Merck to acquire Pandion for $2 billion

  • Merck KGaA (NYSE:MRK) has agreed to acquire Pandion Therapeutics (NASDAQ:PAND) for $60 per share in an all-cash deal valuing Pandion at $1.85B.
  • Under the terms of the agreement, Merck KGaA , through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Pandion, and subsequently Merck KGaA ’s acquisition subsidiary will be merged into Pandion.
  • Pandion’s lead candidate PT101, targeting ulcerative colitis (UC), and systemic lupus erythematosus (SLE), has completed a Phase 1a clinical trial achieving its primary objective of safety and tolerability.

    Merck KGaA fundamentals

    Over the current book year the company from Kenilworth's total revenue could be around 52.51 billion USD (consensus estimates). This is slightly more than 2020's revenue of 47.99 billion USD.

    Historical revenues and results Merck KGaA & Co plus estimates 2020

    financiële analyse

    The analysts expect for 2021 a net profit of 16.58 billion USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 6.56 USD. Based on this the price/earnings-ratio is 11.03.

    Huge dividend Merck KGaA & Co

    Per share the analysts expect a dividend of 2.59 USD per share. The dividend yield is then 3.58 percent. The average dividend yield of the pharmaceutical companies is a low 0.38 percent.

    Merck KGaA & Co's market value equals around 183.77 billion . The Merck KGaA & Co stock was the past 12 months quite volatile. Since last March the stock is 2 percent lower. This year the stock price moved between 65 and 88 dollar.

    Historical stock prices Merck KGaA & Co past 10 years

    equity research merck&co

    Click here for dividend Merck & Co. At 22.10 the stock trades 0.33 percent lower at 72.38 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.